دورية أكاديمية
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies
| العنوان: | Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies |
|---|---|
| المؤلفون: | Cabannes-Hamy, A., Peyrade, F., Jardin, F., Emile, JF., Delwail, V., Mounier, N., Haioun, C., Perrot, A., Fitoussi, O., Lara, D., Delarue, R., André, M., Offner, F., Gherquières, H., Pascal, L., Soussain, C., Lazarovici, J., Schiano, JM., Gaulard, P., Tilly, H., Thieblemont, C. |
| المساهمون: | BONNET, Christophe |
| المصدر: | Cancer Medicine (2018-03) |
| بيانات النشر: | Wiley-Blackwell |
| سنة النشر: | 2018 |
| المجموعة: | University of Liège: ORBi (Open Repository and Bibliography) |
| مصطلحات موضوعية: | Aged 80 and over, NS relapse, DLBCL, ELDERLY, Human health sciences, Hematology, Sciences de la santé humaine, Hématologie |
| الوصف: | peer reviewed ; CNS relapse is reported in 2–5% of diffuse large B-cell lymphoma (DLBCL) patients, dramatically decreasing overall survival (OS). Very few studies address incidence and risk factors of CNS relapse in very elderly patients, a challenging population to treat given their commonly associated comorbidities. A retrospec-tive analysis was performed of 270 DLBCL patients >80years treated between 2004 and 2013 in two multicentre phase II LYSA trials (LNH03-7B, LNH09-7B) evaluating the addition of rituximab or ofatumumab to mini-CHOP as front-line therapy. No patients received CNS prophylaxis. CNS relapse was evaluated according to cumulative incidence, patient characteristics, risk factors, and sur-vival. Median age was 83years (range: 79–95). After a median follow-up of 28.7months, eight patients had CNS relapse (3.0%). Median time between inclusion and CNS relapse was 19.2months (range: 3.2–32.6). Patients survived a median of 1.5months after CNS relapse (range: 0.4–4.1). Median OS from relapse was significantly lower in CNS relapse patients (1.5months, 95% CI: 0.4–3.5) compared to patients with non-CNS relapse (6.6months; 95% CI: 4.6–11.9). No baseline characteristics were associated with CNS relapse. The proportion of patients with CNS disease did not differ significantly between patients with low- intermediate risk according to CNS- IPI and patients with high risk (3% vs. 2.8%, P = 1.00). CNS relapse cumulative incidence in very elderly treatment- naive patients is 1.8% at 2 years and is associated with poor survival. This population had a long median time to CNS relapse. Absence of prophylaxis did not strongly impact CNS relapse incidence. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2045-7634 |
| العلاقة: | urn:issn:2045-7634; https://orbi.uliege.be/handle/2268/240547Test; info:hdl:2268/240547; https://orbi.uliege.be/bitstream/2268/240547/1/CAM4-7-539.pdfTest; scopus-id:2-s2.0-85043983213; info:pmid:29473343 |
| DOI: | 10.1002/cam4.1139 |
| الإتاحة: | https://doi.org/10.1002/cam4.1139Test https://orbi.uliege.be/handle/2268/240547Test https://orbi.uliege.be/bitstream/2268/240547/1/CAM4-7-539.pdfTest |
| حقوق: | open access ; http://purl.org/coar/access_right/c_abf2Test ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.E4064300 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20457634 |
|---|---|
| DOI: | 10.1002/cam4.1139 |